Follow-on grant for Signum's skin disease programme
This article was originally published in Scrip
Executive Summary
Signum Biosciences has been awarded a $1.6 million Small Business Innovation Research (SBIR) phase II grant by the US National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (signal transduction modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.